ArticleThe British journal of general practice : the journal of the Royal College of General Practitioners2003
Understanding why GPs see pharmaceutical representatives: a qualitative interview study.
Article in The British journal of general practice : the journal of the Royal College of General Practitioners, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.PLoS medicine · 2010Pooled it
- Medical professionals' agency and pharmaceuticalization: Physician-industry relations in Russia.Health (London, England : 1997) · 2024Article
- Pharmaceutical Sales Representatives in the United States and China: The Need for Professional Public Space.Health care analysis : HCA : journal of health philosophy and policy · 2022Article
- Article
- Could Contracts between Pharmaceutical Firms and French Veterinarians Bias Prescription Behaviour: A Principal-Agency Theory Approach in the Context of Oligopolies.Antibiotics (Basel, Switzerland) · 2021Article
- Medical, pharmacy and nursing students in the Baltic countries: interactions with the pharmaceutical and medical device industries.BMC medical education · 2020Article
- Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.Health services research · 2019Article
- Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis.Journal of pharmaceutical policy and practice · 2016Review
- Article
- Which pharmaceutical sales representatives' features do slovenian family physicians value?Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2013Article
- Physicians' perceptions of medical representative visits in Yemen: a qualitative study.BMC health services research · 2013Article
- Norwegian medical students' attitudes towards the pharmaceutical industry.European journal of clinical pharmacology · 2010Article
- Prescribers and pharmaceutical representatives: why are we still meeting?Journal of general internal medicine · 2009Article
- Efforts to ban direct-to-consumer advertising in New Zealand: a call to action.The British journal of general practice : the journal of the Royal College of General Practitioners · 2003Article
- How to change clinical behaviour: no answers yet.The British journal of general practice : the journal of the Royal College of General Practitioners · 2003Article
- Confidentiality: consent is not sufficient.The British journal of general practice : the journal of the Royal College of General Practitioners · 2003Article
- Health professional's exposure, attitude, and acceptance of drug promotion by industry representatives: A cross-sectional study in Ethiopia.Science progressArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoctors are aware of the commercial bias in pharmaceutical representative information; nevertheless, such information is known to change doctors' prescribing, and augment irrational prescribing and prescribing costs.
aimTo explore GPs, reasons for receiving visits from pharmaceutical representatives. DESIGN OF STUDY: Qualitative study with semi-structured interviews.
settingOne hundred and seven general practitioners (GPs) in practices from two health authorities in the North West of England.
resultsThe main outcome measures of the study were: reasons for receiving/not receiving representative visits; advantages/disadvantages in receiving visits; and quality of representative-supplied information. Most GPs routinely see pharmaceutical representatives, because they bring new drug information speedily; they are convenient and accessible; and can be consulted with a saving of time and effort. Many GPs asserted they had the skills to critically appraise the evidence. Furthermore, the credibility and social characteristics of the representative were instrumental in shaping GPs' perceptions of representatives as legitimate information providers. GPs also received visits from representatives for reasons other than information acquisition. These reasons are congruent with personal selling techniques used in marketing communications.
conclusionsThe study draws attention to the social and cultural contexts of GP-representative encounters and the way in which the acquisition of pharmacological information within the mercantile context of representative visits is legitimated. This highlights the need for doctors to critically appraise information supplied by representatives in relation to other information sources.
Indexed as
Identifiers
12879831PMC1314573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.